bladder cancer Archives

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Developments

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence enrolling and treating...

July 24, 2019

Developments

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has integrated the i/Blue...

July 15, 2019

Executive Moves

Imagin Medical adds world-renowned bladder cancer expert Dr. Ashish Kamat to SAB

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) named Dr. Ashish Kamat to its scientific advisory board.

April 17, 2019

Feature

Imagin Medical taking bladder cancer imaging to next level

By Len Zehrs Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically...

June 19, 2018

Feature

Micromedic seeking diagnostic partners on multiple fronts

By Len Zehr With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in...

October 25, 2016

Feature

OncoGenex’s OGX-427 drug gaining investor attention

By Len Zehr Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...

March 26, 2013

Tag - bladder cancer

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical adds world-renowned bladder cancer expert Dr. Ashish Kamat to SAB

Imagin Medical taking bladder cancer imaging to next level

Micromedic seeking diagnostic partners on multiple fronts

OncoGenex’s OGX-427 drug gaining investor attention

General

More